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Abstract
Background: Recent and previous studies have shown that guinea pigs can be infected with, and transmit, human
influenza viruses. Therefore guinea pig may be a useful animal model for better understanding influenza infection
and assessing vaccine strategies. To more fully characterize the model, antibody responses following either
infection/re-infection with human influenza A/Wyoming/03/2003 H3N2 or immunization with its homologous
recombinant hemagglutinin (HA) protein were studied.
Results: Serological samples were collected and tested for anti-HA immunoglobulin by ELISA, antiviral antibodies
by hemagglutination inhibition (HI), and recognition of linear epitopes by peptide scanning (PepScan). Animals
inoculated with infectious virus demonstrated pronounced viral replication and subsequent serological conversion.
Animals either immunized with the homologous HA antigen or infected, showed a relatively rapid rise in antibody
titers to the HA glycoprotein in ELISA assays. Antiviral antibodies, measured by HI assay, were detectable after the
second inoculation. PepScan data identified both previously recognized and newly defined linear epitopes.
Conclusions: Infection and/or recombinant HA immunization of guinea pigs with H3N2 Wyoming influenza virus
resulted in a relatively rapid production of viral-specific antibody thus demonstrating the strong immunogenicity of
the major viral structural proteins in this animal model for influenza infection. The sensitivity of the immune
response supports the utility of the guinea pig as a useful animal model of influenza infection and immunization.
Background
The most common mammalian model used for influ-
enza virus research, the mouse, is not susceptible to
infection with many unadapted human influenza A
viruses of the H3N2 serotype and does not shed virus
from the respiratory tract. Ferrets and macaques have
increased tropisms to many primary influenza isolates
but both are expensive to maintain and difficult to
house. Based largely on their recapitulation of human
disease signs, ferrets have also been used to derive sero-
typing reagents for assessing antigenic distance between
isolates and potential vaccine strains. However, recent
reports suggest that ferrets may not faithfully mimic
human immune responses, and that serological tests
using ferret sera may not accurately assess vaccine strain
efficacy [1,2]. Therefore, there is a need to develop addi-
tional permissive small animal models of influenza virus
infection that exhibit virus shedding. Serial samples col-
lected from such animal models allow the investigator
to determine both the titer and duration of virus shed-
ding from individual animals at multiple times without
euthanasia. Further characterization of animal models
capable of replicating and transmitting unadapted
human, avian, and/or swine influenza viruses can be
valuable for studying and testing new and improved
vaccines, immunobiotics and anti-virals. Two promising
alternative animal models, guinea pigs and cotton rats,
have recently been investigated for the analysis of
human influenza virus and influenza vaccine [3,4].
These studies focus on the guinea pig as a model for
influenza. * Correspondence: Tobin@bmi-md.com
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an animal model for influenza immunization and infec-
tion. Guinea pigs are relatively inexpensive and easy to
maintain for larger studies compared to ferrets and
simians. They are readily infected with primary isolates
of human influenza strains, and have potential uses for
virus evolutionary, prophylactic and therapeutic studies
[3]. A small number of reports describing experimental
infection of guinea pigs with human influenza viruses
were published in the 1970 s and 80 s [5-8]. More
recently, we and others have advanced the guinea pig
model for the study of virus infection and spread and as
a vaccine-challenge model [3]. Guinea pigs can be read-
ily infected with human influenza isolates without prior
tissue culture or animal adaptation. The infection in gui-
nea pigs appears to be centered largely in the upper
naso-respiratory tract and the animals can pass the virus
to others via aerosol transmission [9]. A recent study
demonstrated acute viral replication and moderate viru-
lence of the highly pathogenic 1918 pandemic and
H5N1 viruses in addition to low-pathogenicity avian and
human H1N1 viruses in guinea pigs [10].
The overall purpose of the current study was to char-
acterize the immunological responses of guinea pigs
infected with H3N2 virus or immunized with HA
protein so as to assess the value of a guinea pig model
in future immunological assays such as vaccine-chal-
lenge studies. Because of the prophylactic properties of
HA-derived vaccines, and their relative ease of produc-
tion, immune responses of this subunit were studied in
the guinea pig model. The results support the utility of
t h eg u i n e ap i ga sau s e f u la n i m a lm o d e lo fi n f l u e n z a
infection and immunization.
Results
Infection of Guinea Pigs
Four groups of guinea pigs were chosen, (1) a negative
control with no infection, (2)ap o s i t i v ec o n t r o lt h a t
received an infection only, (3) a group that was immu-
nized with low dose of recombinant HA protein, and (4)
another with high dose. ELISA extinction titers of
Group 1, the control group for this serological study,
remained negative and unchanged throughout the study.
Two guinea pigs (Group 2) were inoculated intrana-
sally with 3 × 10
4 plaque-forming units of A/Wyoming/
03/2003 virus, allowed to recover from infection for
5 weeks, and then re-inoculated with the same dose of
virus. Nasal wash samples were collected at 2, 3, 6 and
9 days post infection (dpi). The guinea pigs exhibited no
outward clinical signs of infection and virus was recov-
ered from nasal washes of each animal between 2 and
6 dpi [3]. Peak titers of progeny virus in this study
occurred on day 3 and were in the range of 5 × 10
4 and
2×1 0
5 pfu/mL of nasal wash fluid (Long et al, in
preparation). Serological samples were prepared over the
course of the regimen for analysis of total anti-HA anti-
bodies by HA ELISA, antiviral antibodies by HI assay,
and identification of linear HA epitopes by PepScan
ELISA. Equal volumes of sera from each individual were
used to produce pools for each time point in each
group. To assess the levels of total HA-specific antibo-
dies, serological samples were assayed by ELISA using
plates coated with commercially prepared full-length
Wyoming HA glycoprotein (Figure 1). Inoculation with
virus and subsequent infection of these guinea pigs
resulted in a rise in ELISA titer to the HA protein by
the 2
nd week which continued to increase through
Week 4.
The guinea pigs received a second inoculation of virus
on Week 5. Peak virus titers from nasal wash samples
occurred again on Day 3 and were determined to be 2 ×
10
4 and 3 × 10
5 pfu/mL for the two animals. Anti-HA
ELISA titers rose from 1:100 to 1:10,000 after the
second infection with live virus. Antiviral activities in
t h es e r aw e r em e a s u r e db yH Ia s s a y( F i g u r e1 ) .I nc o n -
trast to the ELISA results, Group 2 HI titers were not
detectable 5 weeks after initial infection, and rose only
after the re-infection. By Week 9, a significant increase
in titer, 64-fold over pre-infected sera, was detectable. In
the following three weeks, this peak titer decreased
slightly.
Figure 1 Analysis of serum pools from infected guinea pigs.
Serum pools were tested for total HA-binding antibodies by
reactivity to full-length HA protein in a standard ELISA (solid), and
antiviral titers using HI assay (dashed). Arrows along X-axis indicate
inoculation dates for Group 2. Error bars for the ELISA extinction
titers are shown, but are not readily seen due to their small size.
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The two immunized guinea pig groups (Groups 3 and 4)
demonstrated similar patterns of increasing antibody
titers over the course of the four recombinant HA pro-
tein inoculations. Two doses of antigen were initially
used to determine the sensitivity of immune reactivity
to the HA antigen prior to vaccine-challenge studies
with similar subunit antigens. Group 3 (lower antigen
dose) ELISA titers initially lagged behind those of
G r o u p4( h i g h e ra n t i g e nd o s e ) ,b u tc a u g h tu pa f t e rt h e
final boost with equivalent amounts of HA (40 micro-
grams) in both groups (Figure 2). Interestingly, the
ELISA titers persisted at high levels for 4 months fol-
lowing the final immunization and showed little sign of
decay. No significant difference was found between the
ELISA titers of Groups 3 and 4, with a confidence level
of p = 0.33 (ANOVA).
Antiviral HI titers for both groups of HA-immunized
animals increased after the second, third, and fourth
inoculation (Figure 2). The inflections of the HI titer
graphs roughly paralleled the anti-HA ELISA titers
throughout the study. After the final boost at week 10,
HI titers continued to rise (91- to 128-fold increase over
the negative control) and persisted for 16 weeks follow-
ing the last immunization, with only a 2- to 4-fold drop
in magnitude. Sera from Group 1 (negative control)
remained negative throughout the study.
The specificity of the immune response to HA protein
was assessed using Western blot analysis (Figure 3).
Full-length recombinant HA protein was electrophor-
esed in a denaturing polyacrylamide gel and transferred
to nitrocellulose. The membrane was cut into strips and
probed with guinea pig sera. Lane 1 shows negative
reactivity observed using sera from mock-immunized
animals. Lanes 2, 3, and 4 demonstrate serological
recognition of HA antigen by animals infected with
influenza virus or immunized with purified HA protein.
Although the samples were boiled in SDS-buffer con-
taining 2-mercaptoethanol, putative dimeric and trimeric
forms of the HA protein are apparent as slower-migrat-
ing species.
PepScan Assays
To characterize reactivity to linear epitopes, serum pools
from sequential bleeds of the infected guinea pigs (Group
2) were tested for binding to a library of overlapping
Wyoming HA peptides (Figure 4). Prior to inoculation
with virus, the sera showed potential reactivity to Pep-
tides 141, 285, and 327 (Panel A). Peptide 141 is within
the A epitope, 285 overlaps the C epitope, and 327 is out-
side of defined epitopes. Although it was unclear why the
pre-infection sera recognized these peptides, reactivity
against 141 and 327 remained throughout the study,
w h i l er e a c t i v i t ya g a i n s t2 8 5w a n e db yt h es e c o n dw e e k
post-infection. Reactivity against Peptides 9 and 453,
both outside of defined epitopes, increased by Week 11
post-infection and was also observed with sera from
Figure 2 Analysis of serum pools from immunized guinea pigs.
Sera pools were tested for antibodies that bind to non-denatured
full-length HA protein by ELISA and are denoted with solid lines.
Sera pools were also tested for antiviral activity by HI, shown with
dashed lines. Negative control animals in Group 1 were
discontinued after 13 weeks. Arrows along X-axis indicate
immunization boost dates. Error bars for the extinction titers are
shown, but due to their small size, are not visible.
Figure 3 Western Blot Analysis of sera from immunized and
infected Guinea Pigs. Full-length recombinant HA sera (Protein
Sciences, Inc.) was electrophoresed in a denaturing polyacrylamide
gel and transferred to membranes. The lanes were cut into strips
and probed with Guinea pig sera to confirm the specificity of
reactivity. Lane 1: Groups 1 (mock infected) sera, 1:1500; lane 2:
Group 2 (influenza infected) sera 1:1500, Lane 3: is Group 3
(immunized with lower concentration of HA protein) sera 1:3000,
and Lane 4: Group 4 (immunized with higher concentration of HA
protein) sera 1:3000.
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and 327 increased in sera from Week 5 post-infection
(Panel C), but returned to pre-immune levels by Week 9
(Panel D).
Immune reactivities of sera from HA-immunized gui-
n e ap i g sw e r ec o m p a r e dw i t hi nfluenza-infected guinea
pigs (Figure 5). Sera from mock-immunized animals
(Group 1, Panels A1, B1, C1, and D1 of Figure 5)
reacted with Peptides 141 and 327, as previously seen
with sera from pre-infected guinea pigs (Figure 4A). As
the mock-immunized guinea pigs aged, they developed
measurable reactivity to Peptide 81, which overlaps the
E epitope.
After immunization with lower dose HA antigen, sera
from Group 3 animals initially increased overall reactiv-
ity against most of the representative peptides in the
panel with enhanced reactivity against Peptides 81, 141,
165, and 327 (Panel B2). Immediately prior to the sec-
ond boost, reactivity against many of the peptides
decreased and reactivity primarily against 81, 141 and
327 was seen (Panel C2), whi c hp e r s i s t e dt h r o u g ht h e
study. In addition, after boosting, weak reactivity against
Peptide 45, in the C epitope, and strong activity against
Peptide 483, outside defined epitopes, were observed
(Panel D2).
Prior to inoculations, sera from the higher dose
i m m u n i z a t i o ng r o u p( G r o u p4 )s h o w e ds i m i l a rl o w
levels of reactivity as seen with the other two immuniza-
tion groups (Panel A3). At Weeks 3, 5, and 12, sera
from Group 4 animals recognized Peptides 81 and 327
with moderate levels of reactivity (Panel B3). Reactivity
against Epitope A Peptides 135 and 141 increased in
Week 3, peaked in Week 5, and then decreased in
Week 12. Similar to what was seen for Group 3, reactiv-
ity against Peptides 45 and 483 were observed in later
bleeds. PepScan data from serum samples of all groups
collected after Week 12 demonstrated patterns of pep-
tide binding similar to those at Week 12 (data not
shown). Table 1 contains a summary of the most highly
reactive peptides recognized by the guinea pig sera.
Mapping reactive peptides to 3-D structure
The position of reactive peptides located on the three-
dimensional structure of the related H3N2 strain X-
31HA was studied (Figure 6, Panels A-D, 1HGG.pdb,
[11]). Figure 6A shows a ribbon diagram of the mono-
meric ectodomain of HA in which residues in epitopes
A-E have been colorized. Figure 6B identifies the loca-
tions of peptides 141 and 327, which were seen in pre-
infected and mock immunized sera. Peptide 141 con-
tains amino acid residues previously mapped to epitope
A (142-146, 150, 152) [12] while peptide 327 is located
in a membrane-proximal position, a previously unde-
fined as an area of antigenic interest. Figure 6C shows
the location of the two peptides identified in PepScans
from influenza infected guinea pigs, Peptides 9 and 453.
Figure 6D identifies the positions of Peptides 135 (also
contained in epitope A) and 483 that were recognized
by sera from immunized animals. As can be seen in Fig-
ure 6, Peptides 9, 453, and 483 are located in the mem-
brane-proximal stem of the HA glycoprotein in a region
previously not noted for containing epitopes.
Discussion
A major aim of our research group is the development
of broadly protective vaccines that stimulate cross-pro-
tective immunity against multiple strains of human
influenza viruses [13,14]. In the process of developing
and testing vaccines for the stimulation of broadened
immunity, it is necessary to raise sera in multiple species
of animals for analysis of cross-strain antiviral responses.
In addition, it would be helpful to assess protection
from cross-strain challenge in multiple animal models.
Because of the attractiveness of the guinea pig model
for infection with influenza, we have characterized the
immune responses after infection or immunization of
guinea pigs. Here we present an immunological
Figure 4 PepScan ELISA of serum pools from guinea pig
infected with influenza virus. Serum pools (1:750) from Group 2
animals were analyzed for recognition of linear epitopes by
reactivity to overlapping peptides bound to microtiter plates.
Sequential bleeds were tested from the prebleed (A) and 2 (B), 5
(C), 9(D), 11 (E) and 12 (F) weeks after the initial infection. Reactivity
to peptides from sera after infection was compared to the results
from the pre-infected sera to identify virus-specific epitopes induced
during infection.
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with an H3N2 virus and those immunized with the
homologous HA glycoprotein, an attractive potential
subunit vaccine candidate.
Contrasting the serological results of infected and
immunized animals provided interesting insights. The
data demonstrated that guinea pigs readily seroconvert
in response to both intranasal inoculations of virus and
immunizations with the same recombinant HA glyco-
protein. A rise in binding antibodies (ELISA positive)
preceded the development of antiviral antibodies as
determined by hemagglutinin-inhibition (HI positive) for
both infected and immunized groups of guinea pigs.
The initial lag period was followed by strong correlation
between the continued elevation of binding and antiviral
(HI) antibodies. ELISA titers rose to approximately
1:100 titers after single inoculations with either infec-
tious virus or purified HA antigen. Peak ELISA titers of
infected animals reached 1:10,000, while those of immu-
nized animals reached 1:100,000. However, if Groups 3
a n d4h a db e e nl i m i t e dt oo n ly two doses, then titers
m a yh a v em o r ec l o s e l ym a t c hed Group 2. Measurable
Figure 5 PepScan ELISA of serum pools from guinea pigs immunized with recombinant HA protein. Group serum pools (1:750 dilution)
were analyzed for recognition of linear epitopes by reactivity to overlapping peptides bound to microtiter plates. The black bars indicate the
magnitude of the ELISA reactivity as a measure of Optical Density (O.D.) for the recognition of specific peptides. Sequential bleeds were tested
from the prebleed (A) and 3 (B), 5 (C), and 12 (D) weeks after the initial immunization. Reactivity to the peptides was compared between the
three groups to identify potential linear epitopes. Group 1: mock immunized negative control group (left column), Group 3: lower dose HA-
immunized (center), Group 4: higher dose HA-immunized (right column).
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nogen. HI titers of both infected and immunized ani-
mals reached approximately 1:1000 and decayed slightly
over time. The lack of measurable antiviral immune
responses observed before the second inoculation of any
of the experimental groups may be due to the lower
sensitivity of the HI assay, and is not necessarily an indi-
cation that the first infection or immunization did not
elicit HI responses. Both ELISA and antiviral antibody
titers persisted for many weeks following the final infec-
tious innocula or boost with HA protein. Little, if any,
decay of ELISA or HI titers were observed through
Week 26 following the final HA immunization at Week
10.
A better understanding of the epitopes recognized by
the anti-HA antibody responses in this experimental
animal model, and how these epitopes compare to the
human immune response, could facilitate more rapid
advancements in vaccine design. Five dominant epitopes
(A-E) of the HA glycoprotein have been previously char-
acterized by both immunological reactivity in humans
and animals, and by evolutionary variability in naturally
infected humans. A PepScan analysis was conducted to
map the linear B cell epitopes and was intended to
Table 1 Sequences of Sero-reactive HA Peptides
Peptide N-Terminus Specificity of Group Recognized by Pre-immune Epitope Amino Acid Sequence
9 Infected No none STATLCLGHHAVPNGTIV
45 Immunized No C SSSTGGICDSPHQILDGE
81 Immunized Yes E NKKWDLFVERSKAYSNCY
135 Immunized No A TSSACKRRSNKSFFSRLN
141 All Yes A RRSNKSFFSRLNWLTHLK
165 Immunized No B NVTMPNNEKFDKLYIWGV
285 Pre-Immune Yes C NGSIPNDKPFQNVNRITY
327 All Yes none QTRGIFGAIAGFIENGWE
453 Infected No none KQLRENAEDMGNGCFKIY
483 Immunized No none NGTYDHDVYRDEALNNRF
Figure 6 Peptides recognized by Guinea pig sera localized on the 3D structure. Panel A shows the monomer structure file of the related
H3N2 HA glycoprotein of A/X-31 (H3N2) colorized to identify the locations of the major epitopes A (green), B (red), C (pink), D (yellow), and E
(orange). Panel B shows the location of HA peptides that were recognized by negative control guinea pig sera: peptides 81, 141, and 327
(peptides colorized in cyan). Panel C shows peptides recognized by infected Guinea pigs: peptides 9, 141, 327 and 453 (peptides colorized in
shades of cyan). Panel D shows peptides recognized by sera from immunized Guinea pig sera: peptides 45, 81, 135, 141, 165, 327 and 483
(peptides colorized in cyan). The structure was drawn from 1HGG.pbd [11] using PyMOL [30].
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derived in other animals and in humans. Analysis of
conformational epitopes recognized by infected and
immunized guinea pigs will be the subject of a future
study. Previous immunological studies using overlapping
peptides to characterize linear epitopes in influenza and
other pathogens have had mixed results [14-19].
Although PepScans have identified epitopes in HIV,
Measles, SARs, and Borna virus, most prior studies with
this type of analysis failed to detect linear epitopes
within the HA glycoprotein [20-22]. However, the con-
tinued improvements in peptide synthesis suggested that
the approach should be revisited and expanded to
encompass the entire HA protein. Interestingly, the data
from this study identified two immunodominant epi-
topes, represented by peptides with N-terminal amino
acids 141 and 327, which are recognized by both pre-
immune and immune sera. While the interpretation of
reactivity by pre-immune sera remains open, these
results suggest that recognition of viral epitopes is pre-
sent in the innate repertoire. If so, it is possible that
pre-infection recognition plays a role in skewing the
immune system towards a more oligoclonal rather than
polyclonal response. Induction of an immune response
limited to a small set of epitopes may accentuate recog-
nition of immunodominant epitopes that are often pre-
sent in regions of high genetic variability in Class II
pathogens [13]. The ability to take advantage of the pro-
pensity of host immune systems to mount strain-specific
immune responses largely limited to variable immuno-
dominant epitopes may be a pathogenesis trait that
influenza and other viruses have evolved so as to
increase fitness on a landscape made more rugged by
host immunity.
Serum from the high dose immunization group
(Group 4) showed increased reactivity to peptides 141
and 135 (Figure 6) which both represent a highly vari-
able and immunogenic loop of Epitope A [23]. Unex-
pectedly, reactivities to additional peptides (9, 327, 453,
and 483) derived from regions outside of previously
defined epitopes, and near the transmembrane domain,
were observed after multiple immunizations and two
infectious innocula. The amino acid sequences at the
cores of these peptides are highly conserved among
influenza A strains. The observation of linear epitopes
does not preclude the reactivity of the sera to more
dominant conformational epitopes that were not
detected by this method. However, in a recent study of
cross-reactive epitopes in avian influenza serotypes,
Meuller et al. identified several linear epitopes in the
HA of H4, H5, and H12 through a similar use of over-
lapping peptide ELISA [24]. We have aligned the sets of
peptides used in both studies to determine analogous
peptides so that the results can be compared more easily
(data not shown). Interestingly, analogues of many of
the H3N2 peptides that were recognized in the present
study were also recognized by sera against the avian HA
glycoproteins. Avian sera recognized analogues to pep-
tides 141 and 327, which were recognized by pre-
immune Guinea pig sera. In addition, avian sera also
recognized analogues to peptides 9, 453, and 483. The
contribution of reactivity to these peptides towards anti-
viral activities will require further investigation. Future
studies have been planned to characterize the PepScan
reactivities of sera from humans infected or immunized
with influenza A/Wyoming/03/2003.
Overall, the current study has provided valuable
immunogenicity data to further characterize immune
responses in a relatively new animal model for human
influenza infection and vaccination.
Conclusions
We present an immunological comparison between gui-
nea pigs infected intranasally with an H3N2 virus, A/
Wyoming/03/2003, and those immunized with recombi-
nant HA subunit from the homologous strain. Sera
from guinea pig treatment groups, collected over a six
month period, were compared serologically for changes
induced by each treatment: total antibodies were mea-
sured by ELISA, antiviral responses by HI assay, and
recognized linear epitopes identified by PepScan ELISA.
Results of this study re-enforce and extend previous
reports characterizing the infection of guinea pigs fol-
lowing inoculation with unadapted human influenza
strains. The infected guinea pigs mounted vigorous
immune responses that had antiviral activities as mea-
sured by HI assay. Guinea pigs immunized with purified
HA protein developed similar antiviral activities. Peps-
can data determined that sera from naïve animals recog-
nize a linear epitope in the defined A epitope and
another epitope near the fusion or HA cleavage sites.
Further studies will be required to determine whether
these innate reactivities are also found in sera from
naïve humans. If so, it will be important to assess
whether these antibodies offer any protective immunity,
or are dysregulatory in nature. Pepscan data also
demonstrated the reactivity of sera from infected and
immunized animals to linear determinants located both
within and outside of previously defined major epitopes.
The change in PepScan profiles over the course of the
immunization and infection regimens appeared to reflect
maturation of the humoral immune responses to linear
epitopes. By altering the immunogenicity of the most
dominant, yet variable, epitopes, it may be possible to
refocus the immune response towards more highly con-
served epitopes to derive a more broadly cross-protec-
tive influenza vaccine [13,14]. Subunit vaccines, along
with well-defined animal models for influenza research,
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the development of future vaccines for both seasonal
and pandemic influenza outbreaks.
Methods
Cells and Virus
Influenza A/Wyoming/03/2003 (H3N2) was obtained
from the Center for Disease Control and Prevention. The
virus was originally derived by reassortment and contains
genes encoding HA and neuraminidase of Wyoming,
with all other genes from A/Puerto Rico/8 H1N1 virus
[25]. The virus was propagated in monolayer cultures of
M a d i n - D a r b yc a n i n ek i d n e y( M D C K )c e l l s( A T C C
#CCL-34) using Dulbecco’s Modified Eagle Medium
(Lonza), supplemented with 7% fetal bovine serum
(Lonza). For plaque assays, virus samples were serially
diluted into 1 mL of phosphate buffered saline (PBS) and
placed into 6-well plates confluent with MDCK cells.
A f t e ra n1 - h o u r( h )i n c u b a t i o n ,t h ei n n o c u l aw e r e
replaced by a mixture of 1% molten agar in complete
growth media. Upon solidification of the agar, the plates
were inverted and incubated in a humidified 37°C incu-
bator. Plaques were typically visible for enumeration or
isolation 3-4 days after inoculation. Prior to introduction
into animals, MDCK propagated virus stocks were titered
using a plaque assay and adjusted to 3 × 10
5 plaque-
forming units/mL (pfu/mL) with sterile saline.
HA Protein Expression and Purification
Recombinant influenza A/Wyoming/03/2003 hemagglu-
tinin (HA) was produced in stably transformed S2 dro-
sophila cells [26,27]. Briefly, the A/Wyoming/03/2003
gene was subcloned from a parental plasmid vector
(a kind gift of Dr. Kanta Subbarao, NIAID, NIH) into
pMT-BiP-V5-His (Invitrogen, Inc.) such that the mature
ectodomain (amino acids 17-513) was in-frame with the
BiP insect cell promoter, and sequences encoding a hex-
ahistadine tract were inserted immediately upstream of
a stop codon. S2 drosophila cells were co-transfected
with the HA expression plasmid and pCoBLAST
(Invitrogen, Inc), and stable transformants selected with
blastocidin (30 micrograms/mL, Thermo Fisher Scienti-
fic). Expression of recombinant HA protein was induced
f o rf o u rd a y sb yt h ea d d i t i o no f1m Mc u p r i cs u l f a t et o
the culture media. After expression, conditioned super-
natants containing the secreted HA protein were clari-
fied at 2,000 × g for 20 min. The HA protein was
purified through a multi-step process including chroma-
tographies on copper-charged Fast Flow Sepharose
(GE Bio) using elution with 50 mM imidazole, lentil lec-
tin agarose (Vector Labs) using elution with 0.5 M
alpha-methly-D-mannoside, and, finally, anion exchange
in DE53 resin (Whatman) at pH 8.8 with elution
in 50-100 mM NaCl. The eluted samples were
concentrated and buffers exchanged after each chroma-
tography step using filtration spin-cartridges with 30,000
molecular weight cut-off membranes (Amicon Ultra
Centrifugal Filter Devices, Millipore). Protein yield
and purity were determined using the Pierce Coomassie
Protein assay reagent with a bovine serum albumin stan-
dard, and Western blotting with comparison to com-
mercially prepared standards of full-length A/Wyoming/
03/2003 HA glycoprotein (a kind gift of Dr. Joseph A.
Rininger, Protein Science Corporation). A mock pre-
paration of the HA ectodomain protein was produced
using the above expression and purification methods,
and stably transformed S2 cells containing the empty
pMT-BiP vector lacking the HA gene for use as a nega-
tive control in immunization experiments.
Guinea Pig Infections and Immunizations
Six to eight weeks of age guinea pigs were obtained from
Harlan-Spraque-Dowley Inc., and animal studies per-
formed at BioCon Inc, Rockville, MD followed appropriate
AAALAC-approved guidelines for the humane treatment
of animals in research. Guinea pigs were divided into four
groups (Table 2) and test bleeds were collected prior to
the study. Group 1 (n = 4, each) guinea pigs were immu-
nized subcutaneously with the mock prepared negative
control protein, and served as a negative control. Group 2
(n = 2), were lightly anesthetized and intranasally inocu-
lated with 1 mL of A/Wyoming/03/2003 influenza virus
(3 × 10
4 pfu/mL). Animals were re-infected at five weeks
after the first inoculation with the same dose of virus.
Guinea pigs in Groups 3 and 4 (n = 4) were subcuta-
neously immunized with recombinant HA protein in
Complete Freund’s Adjuvant (Thermo Fisher Scientific)
and boosted at weeks 3, 5, and 10 with HA protein in
Incomplete Freund’s Adjuvant (Thermo Fisher Scientific)
to characterize the boosting effects of the HA antigen.
Initial experimental design also included a comparison of
increasing antigen load t os t u d yh o wt h ea n i m a l s
responded to increasing concentrations of antigen. This
was an attempt to scale the amount of recombinant HA
protein to that which would be presented by natural infec-
tion. Animals in Group 3 were immunized three times
with 10 micrograms each, and then given a final boost of
40 micrograms at 10 weeks post-prime. Group 4 animals
were immunized three times with 30 micrograms of
recombinant HA, with a final boost of 40 micrograms. At
the same intervals, Group 1 control guinea pigs were
immunized with the mock protein preparation derived
from the insect cell system used to propagate the HA
recombinant antigen.
ELISA and Immunoblot Analysis of Guinea Pig Sera
Guinea pig serum samples were assessed for induction
of specific HA antibody responses using a standard
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96-well plates were coated overnight with 0.1 mL/well
containing 1.5 micrograms of full-length A/Wyoming/
03/2003 HA protein (Protein Science Corporation).
Plates were blocked with 10% nonfat dried milk in PBS
for 2 h at 37°C. Serum samples were serially diluted in
1% milk solution and 100 microliter aliquots were tested
for binding to antigen in triplicate. After 1 h incubation
at 37°C, the plates were washed in PBS containing 0.1%
T w e e n - 2 0( P B S - T )a n dp r o b e dw i t hap e r o x i d a s e -
conjugated goat anti-guinea pig total IgG antibody
(Kirkegaard & Perry Laboratories, Inc., Gaithersburg,
MD, KPL, 1:1000) for 1 h. After additional washes,
bound conjugates were quantitated by the addition of
tetramethylbenzidine (TMB) substrate (KPL) for 90 sec,
followed by an equal volume of 0.1N sulphuric acid.
Plates were read at 450 nm and mean values of triplicate
wells were calculated. Plate backgrounds were deter-
mined from antigen-coated wells detected with second-
ary antibody only. ELISA extinction titers were
calculated as the maximum serum dilutions that
resulted in a signal that exceeded a value that was three
times plate background (approximately 0.15 OD units).
Mean values with error bars equal to one standard
deviation of the triplicate were graphed as a function of
time over the course of the study.
The specificity of immune responses to HA protein
was assessed by Western blot analysis. Samples contain-
ing 30-50 ng of full-length recombinant A/Wyoming/
03/2003 HA protein (Protein Sciences, Inc.) were elec-
trophoresed in 4-20% Tris-Glycine gels (Invitrogen) and
transferred to nitrocellulose membrane. The membrane
was cut such that each replicate lane was in a single
strip, blocked in a solution of 10% nonfat dried milk in
P B S ,a n dp r o b e dw i t hs e r af r o mi m m u n i z e da n d
infected guinea pigs. After washing in PBS-T, the strips
were detected with peroxidase-conjugated goat anti-Gui-
nea pig antibody, washed again, developed with West
Pico Chemiluminescent Substrate (Pierce). The blot was
exposed to X-ray film and images of the strips
assembled for comparison.
Hemagglutination Inhibition Assay (HI)
A standard HI assay was performed in blinded fashion
to assess Wyoming/03-specific neutralizing antibody
levels [28]. Prior to assay, serum samples were treated
Table 2 Guinea Pig Infection and Immunization Regiments
Group # Study Antigen # of Doses Week Dose
1 (n = 4) Neg. Control Mock-produced HA empty pMT-BIP 4 0, 3, 5, 10 30 ug, 30 ug, 30 ug, 40 ug (Total Protein)
2 (n = 2) Infection A/Wyoming/2003 2 0, 5 3 × 10
4 pfu, 3 × 10
4 pfu
3 (n = 4) Immunization (lower Dose) A/Wyoming/2003 HA ectodomain 4 0, 3, 5, 10 30 ug, 30 ug, 30 ug, 40 ug (Total Protein)
4 (n = 4) Immunization (Higher Dose) A/Wyoming/2003 HA ectodomain 4 0, 3, 5, 10 30 ug, 30 ug, 30 ug, 40 ug (Total Protein)
Figure 7 Protein sequence of influenza A/Wyoming/03/2003 hemagglutinin glycoprotein showing location of peptides synthesized for
use in PepScan analysis [GeneBank:EU268227.1].
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heat inactivation for 1 hour at 56°C. Two-fold dilutions
of serum samples were mixed with A/Wyoming/03/2003
virus (at a concentration of 4 hemagglutination units per
well) and incubated for 15 min at room temperature.
0.05 mL of a 0.5% suspension of chicken red blood cells
was added and hemagglutination was assessed after 1 h,
as described.
Peptide Synthesis and Peptide Scanning (PepScan) Assay
To map linear antibody responses, a set of overlapping
peptides (Figure 7) representing amino acids -16
through 513 of the Wyoming HA glycoprotein was
synthesized by Mimotopes, Inc. (Melbourne, Australia)
[29]. Peptide 1 represented the amino terminus of the
precursor protein, including the signal leader sequence,
and was synthesized with a C-terminal linker of four
residues followed by a biotin label. All other peptides
were synthesized with an N-terminal linker and an
N-terminal biotin. The peptides contained 18 residues
and overlapped in sequence with each neighbouring
peptide by 10 residues. Peptides were synthesized with a
biotin conjugate to facilitate binding to streptavidin-
coated microtiter plates. Figure 7 shows the overlap
design of the peptides and the N-terminus number
assigned to each individual peptide.
To assess immune recognition of linear epitopes, pep-
tides were bound to plates and tested for reactivity to
serum samples. Briefly, 0.1 mL of a 4 microgram/mL
solution of streptavidin (Promega) was introduced into
each well of Nunc Maxisorp plates and allowed to eva-
porate overnight at 25°C. The plates were washed ten
times with PBS-T, blocked for 2 h with PBS-T and evac-
uated. For each peptide, 0.1 mL of a solution, adjusted
to 20 microgram/mL, was placed into a well and
allowed to bind overnight at 25°C, and rinsed with PBS-
T. The plates were blocked overnight with 10% nonfat
dried milk, at 4°C, and rinsed with PBS-T. Guinea pig
serum samples were diluted in 1% milk and incubated
in the wells for 2 h at 37°C. Plates were washed with
PBS-T, probed with an 1 micrograms/mL solution of
peroxidase-conjugated goat anti-guinea pig IgG for 1 h
at 37°C, washed again, and developed with TMB solu-
tion. Bound antibody was detected in a standard plate
reader using the same methods as described above for
ELISA detection.
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